Companies › GC Biopharma
8 active drug programs in 8 registered trials: 5 Phase 1, 3 Phase 3; Metabolic and endocrine, Infectious disease, Immunology, Other; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GC5107 Immune Globulin Intravenous (Human) - pooled human immunoglobulin replacement therapy | – | Phase 3 | Primary Immune Deficiency | Nov 2026 |
| MG1111 (Barycela inj.) Live attenuated varicella-zoster virus vaccine | – | Phase 3 | Varicella (Chickenpox) | Aug 2027 |
| Undiluted I.V.-Hepabig inj (GC5103) Hepatitis B immunoglobulin (anti-HBs antibody) | – | Phase 3 | Hepatitis B | – |
| GC4006A COVID-19 preventive vaccine | – | Phase 1 | COVID - 19 | May 2027 |
| GC1123 Idursulfase-β (Hunter syndrome enzyme replacement therapy) | IDS | Phase 1 | Mucopolysaccharidosis II | Jun 2027 |
| GC1130A Recombinant human heparan N-sulfatase (rhHNS) | SGSH | Phase 1 | Sanfilippo Syndrome Type A | Jun 2027 |
| HM15421/GC1134A unclear - Fabry disease modulator | – | Phase 1 | Fabry Disesase | Aug 2028 |
| GC3111B Vaccine immunization | – | Phase 1 | Tetanus-diphtheria-acellular Pertussis (Tdap) | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06997627 | GC3111B | Phase 1 | Tetanus-diphtheria-acellular Pertussis (Tdap) | Other | May 2026 |
| NCT05686759 | Undiluted I.V.-Hepabig inj (GC5103) | Phase 3 | Hepatitis B | Infectious disease | Jun 2026 |
| NCT04565015 | GC5107 | Phase 3 | Primary Immune Deficiency | Immunology | Nov 2026 |
| NCT07728396 | GC4006A | Phase 1 | COVID - 19 | Infectious disease | May 2027 |
| NCT05422482 | GC1123 | Phase 1 | Mucopolysaccharidosis II | Metabolic and endocrine | Jun 2027 |
| NCT06567769 | GC1130A | Phase 1 | Sanfilippo Syndrome Type A | Metabolic and endocrine | Jun 2027 |
| NCT07054099 | MG1111 (Barycela inj.) | Phase 3 | Varicella (Chickenpox) | Vaccines | Aug 2027 |
| NCT06858397 | HM15421/GC1134A | Phase 1 | Fabry Disesase | Metabolic and endocrine | Aug 2028 |
Takeda Denali Therapeutics REGENXBIO Ultragenyx Pharmaceutical
Xiamen Amoytop Biotech CSPC Ouyi Pharmaceutical Hudson Biotech Hangzhou Sciwind Biosciences BioMarin Pharmaceutical
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.